Diabetes drug under new FDA review

by on 10/07/10 at 2:44 pm

WASHINGTON — Federal health scientists have panned a GlaxoSmithKline study that the company used to defend the safety of its embattled diabetes drug Avandia, a once blockbuster-seller that has fallen out of favor because of potential ties to heart attacks.

Read more.

Leave a Reply